The estimated Net Worth of Charles Pauling Semba is at least $131 Tisíc dollars as of 23 June 2023. Charles Semba owns over 12,787 units of DiaMedica Therapeutics stock worth over $131,150 and over the last 3 years Charles sold DMAC stock worth over $0.
Sign up
Charles Semba DMAC stock SEC Form 4 insiders trading
Charles has made over 1 trades of the DiaMedica Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Charles bought 12,787 units of DMAC stock worth $49,997 on 23 June 2023.
The largest trade Charles's ever made was buying 12,787 units of DiaMedica Therapeutics stock on 23 June 2023 worth over $49,997. On average, Charles trades about 1,827 units every 0 days since 2021. As of 23 June 2023 Charles still owns at least 29,943 units of DiaMedica Therapeutics stock.
You can see the complete history of Charles Semba stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Charles Semba's mailing address?
Charles's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.
Insiders trading at DiaMedica Therapeutics
Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg a David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.
What does DiaMedica Therapeutics do?
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
What does DiaMedica Therapeutics's logo look like?
Complete history of Charles Semba stock trades at DiaMedica Therapeutics
DiaMedica Therapeutics executives and stock owners
DiaMedica Therapeutics executives and other stock owners filed with the SEC include:
-
Dietrich John Pauls MBA,
Pres, CEO & Director -
Rick Pauls,
President, Chief Executive Officer, Director -
Dr. Harry W. Alcorn Jr., Pharm.D.,
Sr. VP of Clinical Operations -
Scott B. Kellen C.A.,
CFO & Company Sec. -
James Parsons,
Director -
Michael Giuffre,
Independent Director -
Jerry Xiao,
Director -
Harry Alcorn,
Director -
Paul Papi,
Vice President - Business Development -
Sydney Gilman,
Vice President - Regulatory Affairs -
Scott Kellen,
Chief Financial Officer, Corporate Secretary -
Richard Pilnik,
Independent Chairman of the Board -
Dr. Edward G. Calamai Ph.D.,
Consulting Head of Manufacturing -
Tanya Lewis,
Director -
David J. Wambeke,
Chief Business Officer -
Jantrill Ab Stahlberg,
-
Dietrich John Pauls,
President and CEO -
Zhenyu Xiao,
Director -
Todd A. Verdoorn,
Chief Scientific Officer -
Koch Thomas Tom Enterprise ...,
-
Koch Thomas Tom Enterprise ...,
-
Charles Pauling Semba,
Director -
Amy L. Burroughs,
Director -
Kirsten L Gruis,
Chief Medical Officer -
Dominic R Cundari,
Chief Commercial Officer -
Julie Van Orsdel Daves,
SVP Clinical Development Oper. -
Masuoka K. Lorianne,
Chief Medical Officer -
Richard Kuntz,
Director